ADMA Biologics
ADMA
13 hedge funds and large institutions have $66.8M invested in ADMA Biologics in 2014 Q4 according to their latest regulatory filings, with 13 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
64.31% more ownership
Funds ownership: 0% → 64.31% (+64%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aisling Capital
New York
|
+$41.3M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$10M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.84M |
| 4 |
BC
Broadfin Capital
New York
|
+$4.45M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$4.12M |
Top Sellers
ADMA Hedge Fund Activity: Q4 2014 in Review
13 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q4 2014, worth a combined $66.8M.
Buyers outnumbered sellers: 13 funds opened new ADMA positions and 0 closed out — a net gain of 13 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Aisling Capital, opening a new position worth an estimated $41.3M.
- 13 institutional investors held ADMA Biologics (ADMA) as of Q4 2014, up from 0 in Q3 2014.
- Funds reported $66.8M of ADMA Biologics stock for Q4 2014.
- 13 funds opened new ADMA Biologics positions in Q4 2014 and 0 closed out, a net change of +13 holders.
- The largest ADMA Biologics buyer in Q4 2014 was Aisling Capital, an estimated $41.3M added.
Based on aggregated 13F filings for Q4 2014.